Pharmacological inhibition of c-Jun N-terminal kinase signaling prevents cardiomyopathy caused by mutation in LMNA gene

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 7-8, 2010, Pages 632-638

  Wu, Wei ^a   Shan, Jian ^a   Bonne, Gisèle ^b,c,d   Worman, Howard J ^a   Muchir, Antoine ^a  

^a Columbia University ^*  (United States)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cardiomyopathy; Emery Dreifuss muscular dystrophy; JNK; Lamin; MAP kinase

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; LAMIN A; NATRIURETIC FACTOR; PLACEBO; RNA; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DILATATION; DRUG INHIBITION; GENE MUTATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SARCOMERE; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTHRACENES; CARDIOMYOPATHIES; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION; HEART; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LAMIN TYPE A; MICE; MICE, TRANSGENIC; MUTATION; MYOCARDIUM; NATRIURETIC PEPTIDES; SIGNAL TRANSDUCTION;

MUS;

EID: 77953810973     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.04.001     Document Type: Article

References (20)

1. Bonne G., Di Barletta M.R., Varnous S., Becane H.M., Hammouda E.H., Merlini L., Muntoni F., Greenberg C.R., Gary F., Urtizberea J.A., Duboc D., Fardeau M., Toniolo D., Schwartz K. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat. Genet. 1999, 21:285-288.
2. Muchir A., Bonne G., van der Kooi A.J., van Meegen M., Baas F., Bolhuis P.A., de Visser M., Schwartz K. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum. Mol. Genet. 2000, 9:1453-1459.
3. Fatkin D., MacRae C., Sasaki T., Wolff M.R., Porcu M., Frenneaux M., Atherton J., Vidaillet H.J., Spudich S., De Girolami U., Seidman J.G., Seidman C., Muntoni F., Müehle G., Johnson W., McDonough B. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N. Engl. J. Med. 1999, 341:1715-1724.
4. Meune C., Van Berlo J.H., Anselme F., Bonne G., Pinto Y.M., Duboc D. Primary prevention of sudden death in patients with lamin A/C gene mutations. N. Engl. J. Med. 2006, 354:209-210.
5. Muchir A., Pavlidis P., Decostre V., Herron A.J., Arimura T., Bonne G., Worman H.J. Activation of MAPK pathway links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy. J. Clin. Invest. 2007, 117:1282-1293.
6. Arimura T., Helbling-Leclerc A., Massart C., Varnous S., Niel F., Lacene E., Fromes Y., Toussaint M., Mura A.M., Keller D.I., Amthor H., Isnard R., Mallisen M., Schwartz K., Bonne G. Mouse model carrying H222P-lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum. Mol. Genet. 2005, 14:155-169.
7. Muchir A., Shan J., Bonne G., Lehnart S.E., Worman H.J. Inhibition of extracellular signal-regulate kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. Hum. Mol. Genet. 2009, 18:241-247.
8. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 2001, 98:13681-13686.
9. Mizuno Y., Yoshimura M., Harada E., Nakayama M., Sakamoto T., Shimasaki Y., Ogawa H., Kugiyama K., Saito Y., Yasue H. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 2000, 86:1036-1040.
10. Muchir A., Worman H.J. The nuclear envelope and human disease. Physiology 2004, 19:309-314.
11. Zanolla L., Zardini P. Selection of endpoints for heart failure clinical trials. Eur. J. Heart Fail. 2003, 5:717-723.
12. White H.D., Norris R.M., Brown M.A., Brandt P.W., Whitlock R.M., Wild C.J. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987, 76:44-51.
13. Hamer A.W., Takayama M., Abraham K.A., Roche A.H., Kerr A.R., Williams B.F., Ramage M.C., White H.D. End-systolic volume and long-term survival after coronary artery bypass graft surgery in patients with impaired left ventricular function. Circulation 1994, 90:2899-2904.
14. Han H., Boyle D., Chang L., Bennett B., Karin M., Manning A., Firestein G.S. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 2001, 108:73-81.
15. Tibbles L.A., Woodgett J.R. The stress-activated protein kinase pathways. Cell. Mol. Life Sci. 1999, 55:1230-1254.
16. Minden A., Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim. Byophys. Acta 1997, 1333:85-104.
17. Ghosh A.K. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp. Biol. Med. 2002, 227:301-314.
18. Rossert J., Terraz C., Dupont S. Regulation of type I collagen genes expression. Nephrol. Dial. Transplant. 2000, 15:66-68.
19. Stebbins J.L., De S.K., Machleidt T., Becattini B., Vazquez J., Kuntzen C., Chen L.H., Cellitti J.F., Riel-Mehan M., Emdadi A., Solinas G., Karin M., Pellecchia M. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl. Acad. Sci. USA 2008, 105:16809-16813.
20. Wong K.K. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat. Anticancer Drug Discov. 2009, 4:28-35.